Merck Looks into Buyout of Seagen

Merck is considering buying biotech company Seagen, according to The Wall Street Journal  

Sources told the publication that there will be no deal imminent due to regulatory approval challenges. Should Merck not complete the purchase, the companies could reach a marketing agreement.

Merck has the financial wherewithal to buy Seagen, as its market value is $215 billion, while Seagen’s is $30 billion.

The two companies are currently collaborating on two projects. In the first case, ladiratuzumab vedotin is an antibody-drug that targets tumors expressing LIV-1, a zinc transporter protein. The other study involves Tukysa (tucatinib) in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC). In a Phase II MOUNTAINEER clinical trial, the latter achieved positive topline results.

Follow us:

Share this article:

LinkedIn

Sign Up to our newsletter

Sign up to our newsletter to stay up to date with the latest industry news 

At Easyfairs, we take your privacy seriously and will only use the information we collect or receive about you in accordance with our privacy policy. If you change your mind you can unsubscribe at any time.